

## Rezvoglar<sup>™</sup> (insulin glargine-aglr) – New interchangeable biosimilar approval

- On November 16, 2022, the [FDA approved](#) Eli Lilly's [Rezvoglar \(insulin glargine-aglr\)](#), *interchangeable* biosimilar to Sanofi's [Lantus<sup>®</sup> \(insulin glargine\)](#).
  - Rezvoglar was previously [FDA-approved](#) as biosimilar to Lantus on December 17, 2021.
  - This is the second *interchangeable* biosimilar approval for Lantus. Viatris/Biocon Biologics' [Semglee<sup>®</sup> \(insulin glargine-yfgn\)](#) was approved on July 28, 2021 as the first interchangeable biosimilar to Lantus. Semglee launched on November 16, 2021.
- Rezvoglar, Semglee and Lantus share the same indication: to improve glycemic control in adult and pediatric patients with diabetes mellitus.
  - Rezvoglar, Semglee and Lantus are not recommended for treating diabetic ketoacidosis.
- An interchangeable biosimilar product may be substituted for the reference product by the pharmacist without the intervention of the prescriber.
  - The substitution can occur at the pharmacy, a practice commonly called “pharmacy-level substitution”— much like how generic drugs are substituted for brand name drugs, subject to state pharmacy laws, which vary by state.
- Eli Lilly's launch plans for Rezvoglar are pending. Rezvoglar will be available as a 100 mg/mL solution in a 3 mL single-use, prefilled pen (KwikPen<sup>®</sup>).